XNAS · Biotechnology
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$95.02-3.79%
Model Target
$66.91
today's free Model Target
Implied downside
-29.6%
vs the Nov 10, 2026 close
Valuation methods
the methods behind the target
TickerWhale Score
79/100
Strong
Score components
TickerWhale View
Kiniksa Pharmaceuticals International plc. - scores 79 out of 100 overall, which we rate strong. Quality & growth is its strongest area and Sentiment Signal its weakest.
What helps
- Technical
- Quality & growth
- Valuation
What to watch
Quality & growth
30%98Strong
- Revenue growth 58.8%
- EPS growth 2325.0%
Valuation
25%63Positive
- P/E 98.2
- EV/Sales 9.3
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#3 / 139sector rank by TickerWhale Score
TickerWhale Score 79 vs sector average 54.6 (+24.4)
Revenue growth (industry)Top 29%
Gross margin (industry)Top 43%
Return on equity (industry)Top 25%
P/E (industry)Pricier than 79%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
91/100Strong vs universe
Ranks 91st of 100 covered names on our technical composite — the composite itself scores 81/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
4 buy · 2 sell · 2 neutral of 8 votes
TickerWhale rates KNSA's technical setup strong — 91st percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+53.1%
- vs 50-day+17.0%
Momentum
Mixed
- RSI (14)59 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rsell
Trend
Constructive
- ADX (14) trend strength23· trending
- MACD (12,26,9)buy(histogram 0.744)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 2 sell · 2 neutral.
Result — 4 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)98.2
- P/S (TTM)9.4
- P/B12.1
- EV/EBITDA—
- EV/Sales9.3
- PEG—
Profitability & returns
- Gross margin89.8%
- Net margin9.6%
- ROE12.8%
- Debt/Equity0.13
Growth
- Revenue growth (YoY)58.9%
- EPS growth (YoY)2325.0%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $7.9B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Today’s free Model Target
One company’s target is free to everyone every trading day, and today it is KNSA. The estimate is computed by the nightly valuation model — no analyst opinion and no AI arithmetic — and it changes when the model runs again.
Pro adds the range around it, the independent methods behind it and the target on every other name. See Pro →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KNSACurrentKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% | ||
| OSCROscar Health Inc - | 76 | 71 | 20.3 | — | 5.4 | 0.5 | $33.47 | +4.14% | +43.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.